When the liver becomes badly scarred (a condition called cirrhosis), blood meets resistance as it flows through. Pressure builds and is pushed back into the veins of the food pipe, which can swell into what doctors call varices. If a large varix bursts, the bleeding is sudden and dangerous.
Because of that risk, patients with cirrhosis are usually sent for an endoscopy: a thin camera passed down the throat to look for varices. It is a good test, but it is uncomfortable, needs sedation, and turns out to be unnecessary for many of the people who have it. Patients with early, stable cirrhosis often have no dangerous varices at all, and gain nothing from the procedure.
So the question our team set out to answer was simple to state and hard to settle: can we tell in advance, without the camera, who is safe to skip it?

The idea we were testing
There is already an international answer, known as the Baveno criteria, and the rule is plain. If a patient's liver stiffness is low, measured by a painless scan called FibroScan, and their platelet count is high enough, the chance of a dangerous varix is so small that endoscopy can be safely deferred. FibroScan takes a few minutes and feels like an ultrasound; a platelet count comes from a routine blood test. Together they cost a fraction of an endoscopy.
The Baveno rule works well in Europe and Asia, but most of the patients it was built on had cirrhosis from viral hepatitis or alcohol. In Kuwait the picture is different: the leading cause is fatty liver disease linked to obesity and diabetes, now called MASLD. That matters, because extra fat and inflammation can make a liver read as "stiffer" on the scan than its internal pressure would suggest. If the scan reads high for the wrong reason, a rule built on stiffness might misfire in exactly the patients we see most.
No one had ever tested this properly in a Gulf Arab population. That gap is what our study set out to fill.

What we did
We followed 380 adults with early-stage cirrhosis at Al Adan Hospital. Each had the two simple measurements, a FibroScan and a platelet count, and then had the endoscopy too, so we could check the prediction against the truth. Two out of three had fatty-liver-related cirrhosis, and many were living with obesity, which made this the right group to stress-test the rule.
We then asked: how often would the simple rule have wrongly cleared someone who actually had dangerous varices? Did it hold up in patients with obesity? And could a second tool, designed for fatty liver disease, do better at the opposite job: correctly flagging patients who genuinely need treatment?

What we found
The main result was reassuring. Among the patients the rule identified as low-risk, the miss rate, the share who turned out to have dangerous varices after all, was 1.4%. That sits under the 5% safety limit the field agreed on, which means the rule was safe to use even in our high-obesity, fatty-liver population. Just over a third of patients could have avoided endoscopy entirely. In the patients with fatty liver but no obesity, the rule performed flawlessly.
We also tested a more relaxed version of the rule that clears more people. That one failed our safety check in patients with obesity: it missed too many dangerous varices. Our reading is that it should not be used in this group. Stretching the threshold catches patients whose scan reads high because of body weight, not because their varices are safe.
The last piece was about the opposite mistake. The standard way of flagging high-risk patients tends to over-treat people with obesity, sending some for preventive treatment they don't actually need. A tool called ANTICIPATE-NASH, which adjusts for body weight, cut that over-treatment roughly in half. It worked in our patients without needing to be re-tuned for the region, which suggests it can be picked up and used here directly.

Why it matters
Together these findings point to a practical, tiered approach for cirrhosis clinics in Kuwait and, we suspect, across the Gulf. Use the simple, conservative rule to spare endoscopies safely; drop the relaxed version in patients with obesity, where it isn't safe; and use the weight-adjusted tool to decide who truly needs preventive treatment.
For a patient, that can mean skipping an uncomfortable procedure they never needed. For a health system, it means endoscopy lists freed up for the people who genuinely require them. And for a region where fatty liver disease is now the dominant cause of cirrhosis, it means we finally have local evidence rather than borrowed assumptions.

What comes next
Our study was run at a single hospital, so the next step is to repeat it across other centres in the Gulf. We also could not measure spleen stiffness, a newer scan that reflects liver pressure more directly and is becoming central to this field; adding it is a clear priority for our next study. And as newer weight-loss and diabetes treatments change how the liver behaves on these scans, the rules will need to be checked again over time.

None of this replaces clinical judgement. But it gives doctors here a way to ask, before reaching for the camera, whether the camera is really needed. Often the honest answer is no, and now we have the numbers to say so.